Business Wire

Solifi Acquires DataScan, Expands Automobile Wholesale Finance and Inventory Risk Management Solutions

23.9.2025 22:47:00 CEST | Business Wire | Press Release

Share

Solifi, a global leader in secured finance technology, today announced the acquisition of DataScan, a trusted North American leader in wholesale finance and inventory risk management.

Founded in 1989 and headquartered in Alpharetta, GA, DataScan has been at the forefront of the wholesale finance and risk category for more than 30 years, serving over 45 major banks and captive lenders. Its core offerings include:

  • Wholesale Intelligence: Loan servicing for wholesale lenders across North America
  • RiskGauge: A digital audit platform modernizing legacy field audits into scalable, data-driven risk management
  • Onsite: Human-verified inventory and asset audits by field specialists

Expanding Solifi’s Open Finance Platform

The acquisition extends Solifi’s automotive offering and Open Finance Platform technology with proven, modern wholesale solutions. The combination of complementary technologies and expertise reinforces Solifi’s position as a premier global provider of end-to-end secured finance technology across auto, wholesale/floorplan, equipment, working capital, and asset-based lending. By integrating DataScan’s wholesale lending and inventory risk solutions with Solifi’s API-driven, cloud-based Open Finance Platform, customers will gain greater access to data and a connected commercial ecosystem designed to strengthen confidence, improve efficiency, lower costs, and accelerate growth.

“This acquisition underscores Solifi’s commitment to innovation, expertise, and leadership,” said Dan Corazzi, CEO of Solifi. DataScan brings proven automotive wholesale, floorplan, and risk audit capabilities that strengthen our Open Finance Platform and support our vision of being a leader across equipment, auto, wholesale, and working capital finance. Just as importantly, we’re excited to welcome Brian and the DataScan associates into the Solifi family.”

“Joining Solifi marks an exciting new chapter for DataScan and our customers,” said Brian Koprowski, CEO and now President and General Manager of DataScan. “Our customers can expect continuity in the solutions and service they trust today, while also gaining the benefits of Solifi’s global reach, scale, and investment in cloud and AI innovation. Together, we’re bringing the best of both organizations to the markets we serve.

Customer Continuity & Innovation Forward

Customers of both companies will continue with their existing service level commitments. DataScan will operate under the “DataScan by Solifi” brand. Brian Koprowski will continue to lead the DataScan business as President and General Manager, joining Solifi’s Executive Leadership Team.

The combined roadmap aims to accelerate digital audit innovation with DataScan’s RiskGauge solution, while expanding wholesale finance capabilities into new global markets.

Goodwin Procter LLP provided legal counsel to Solifi. TD Securities served as exclusive financial advisor and Kirkland & Ellis LLP provided legal counsel to DataScan. Financial terms of the transaction were not disclosed.

About Solifi
Solifi delivers a global portfolio of end-to-end, integrated solutions for secured finance, including equipment finance, auto finance, wholesale/floorplan finance, working capital, and asset-based lending. Our Open Finance Platform (OFP) is trusted by the world’s leading banks, captive finance companies, and independents. With more than 50 years of industry experience and 600 employees across North America, Europe, APAC, and South Africa, Solifi brings together proven expertise and modern cloud technology to help customers protect, scale, and grow their businesses.
www.solifi.com

About DataScan
Headquartered in Alpharetta, GA, DataScan has been a category leader in wholesale finance and risk management for more than 30 years. Serving over 45 major banks and captive lenders, DataScan’s solutions include Wholesale Intelligence, RiskGauge, and Onsite, delivering trusted, data-driven insights that transform inventory and risk management for lenders.
www.onedatascan.com

About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five core sectors – technology, business services, financial services, healthcare and consumer. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has more than 160 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.

About Thoma Bravo
Thoma Bravo is one of the largest software-focused investors in the world, with approximately $181 billion in assets under management as of June 30, 2025. Through its private equity, growth equity and credit strategies, the firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Leveraging Thoma Bravo’s deep sector knowledge and strategic and operational expertise, the firm collaborates with its portfolio companies to implement operating best practices and drive growth initiatives. Over the past 20+ years, the firm has acquired or invested in approximately 555 companies representing approximately $285 billion in enterprise value (including control and non-control investments). The firm has offices in Chicago, Dallas, London, Miami, New York, and San Francisco. For more information, visit Thoma Bravo’s website at www.thomabravo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250923509298/en/

Contacts

Media:
Billy Cripe
bcripe@solifi.com
US: +1 612 851 3200
UK: +44 1908 576 699

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye